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Abstract: Osteoporosis is a skeletal metabolic disease characterized by a compromised bone 
fragility, leading to an increased risk of developing spontaneous and traumatic fractures. 
Osteoporosis is considered a multifactorial disease and fractures are the results of several 
different risk factors both extra- and intraskeletal. Thus bone fragility can be the end point 
of several different causes: a) failure to reach an optimal peak bone mass during growth; b) 
excessive bone resorption resulting in decreased bone mass and microarchitectural deterioration; 
c) inadequate formation upon an increased resorption during the process of bone remodeling. 
The pharmacological therapeutical options, available to date, are directed on prevention of 
fractures. The aim of this paper is to describe the activities and the mechanisms of action, as 
known at present, of the most used therapies for osteoporosis and their clinical implications. 
Improvement of knowledge in this ﬁ  eld will allow us to further improve therapeutical choices 
and pharmacological interventions.
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Introduction
Osteoporosis is a bone metabolic disease characterized by a compromised skeletal 
fragility, leading to an increased risk of developing spontaneous and traumatic fractures 
(NIH 2001). Osteoporosis has been deﬁ  ned a social disease due to its high impact on 
mortality and morbidity and to the alterations on the quality of life of patients affected 
(Kado et al 1999; Gold 2001).
Skeletal fragility can be the result of several different causes: a) failure to reach 
an optimal peak bone mass both in terms of mass and strength during growth; b) 
excessive bone resorption resulting in decreased bone mass and microarchitectural 
deterioration; c) inadequate formation upon an increased resorption during the process 
of bone remodeling. What is clear today is that this disease is mainly the consequence 
of an imbalance of the physiological process of bone turnover (or coupling), with the 
lack of the equilibrium between the activity of osteoblasts and osteoclasts.
The pharmacological therapeutical options, available to date, are directed on 
prevention of fractures and must be then chosen on their antifracturative efﬁ  cacy, 
since fractures trigger back pain (vertebral fracture), limit activity, and often conﬁ  ne 
patients to bed (Klotzbuecher et al 2000; Lindsay et al 2001).
Additionally, multiple vertebral fractures cause kyphosis and loss of height and 
fracture at any site increases the risk for subsequent fracture: indeed up to 20% of 
women who have an incident vertebral fracture will develop a subsequent fracture 
within one year. Nowdays different therapeutical options can be classiﬁ  ed according Clinical Interventions in Aging 2007:2(1) 56
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to the mechanism(s) of action by which prevent bone 
loss. Bisphosphonates (Diez-Perez 2002) and selective 
estrogen receptor modulators (SERMs) can be classiﬁ  ed 
as antiresorptive agents since their main role is to block 
osteoclast activity and their effects are aimed to block either 
further decrease of bone density or deterioration of skeletal 
microarchitecture (Ettinger et al 1999; Chesnut et al 2000); 
in contrast, teriparatide (recombinant human parathyroid 
hormone), the newest agent against osteoporosis (Hodsman 
et al 2005), is anabolic with respect to bone and therefore, 
bone microarchitecture is restored with increase in both 
cortical thickness and connectivity.
The aim of this paper is to describe the currently known 
activities and the mechanisms of action of the most used 
therapies for osteoporosis and their clinical implications.
Physiopathological mechanism 
of bone homeostasis
Bone is a highly specialized form of connective tissue, 
whose primary functions are mechanical support, physical 
protection for organs and soft tissue, and storage for systemic 
mineral homeostasis. Indeed, the skeleton is an extremely 
complex tissue which, to accomplish the above mentioned 
functions, has and maintains contradictory properties: 
strength and lightness, stiffness and ﬂ  exibility (Seeman 
2003b). In this complex living tissue the extracellular matrix 
is mineralized, conferring marked rigidity and strength, but 
also maintaining some elasticity to allow ﬂ  exibility (Seeman 
2003b; Migliaccio et al 2004).
This sophisticated equilibrium is due to and maintained 
by a dynamic process, called remodeling, characterized by 
a balance, referred to as coupling, between the activity of 
osteoclasts, the bone resorbing cells and osteoblasts, the 
bone forming cells (Boivin and Meunier 2003; Seeman 
2003b). During development and growth, bone formation 
exceeds bone resorption (modeling) with a net gain in bone 
mass (Raisz 2001; Boivin and Meunier 2003; Seeman 
2003b) while in mature individuals, bone loss consequent 
to osteoclast resorption is replaced by appropriate bone 
formation, allowing bone restoration. Many factors, such as 
genetic, nutritional, hormonal, and environmental inﬂ  uence 
osteoclast and osteoblast differentiation, recruitment and 
activity, acting through life to maintain a physiological 
remodeling (Manolagas 2000; Migliaccio et al 2004). 
Recently attention has been focused on the role of local 
factors such growth factors and cytokines in the development 
of osteoporosis (Paciﬁ  ci et al 1991; Jilka et al 1992; Raisz 
1993). For instance, estrogens’ effects on osteoclast activity 
has been claimed to be both direct and indirect, through 
a paracrine regulation via osteoblast cytokines (Paciﬁ  ci 
et al 1991; Jilka et al 1992; Raisz 1993; Hughes et al 
1996; Yasuda et al 1998; Burgess et al 1999; Taranta et al 
2002; Cenci et al 2003). Estradiol appears to decrease the 
responsiveness of osteoclasts to factors such as receptor 
activator of nuclear factor kappa B ligand (RANKL) and 
macrophage-colony stimulating factor (M-CSF), released 
in the bone microenvironment by osteogenic cells and by 
marrow stroma (Hughes et al 1996; Taranta et al 2002). 
Additionally, estrogen deﬁ  ciency might also increase the 
lifespan of osteoclasts while the lifespan of osteoblasts 
would be decreased (Hughes et al 1996; Taranta et al 
2002). Thus, bone loss accelerates in women after surgical 
or natural menopause because estrogen withdrawal is 
associated with increased remodeling intensity (activation 
frequency) in favor of bone resorption, with development 
of osteopenia.
Therefore, optimal antifracture efﬁ  cacy results if drug 
therapy is targeted to the underlying cellular abnormality 
(anabolic therapy for osteoporotic individuals with reduced 
bone formation, antiresorptive therapy for patients with 
increased resorption).
Antiresorptive therapy
Antiresorptive agents decrease the number, activity, 
and life span of osteoclasts by restoring bone density by 
decreasing remodeling of bone. These agents are capable 
of preserving bone mass, enhancing mineralization of 
the bone matrix, potentially stabilizing the trabecular 
microarchitecture, and reducing fracture rates. However 
it must be pointed out that not all antiresorptives act in the 
same manner. For instance, Raloxifene (RAL), showed 
its efficacy by significantly increasing bone mineral 
density (BMD), with sustained effect during time, both at 
lumbar spine and at the hip (Bjarnason et al 2001; Delmas 
et al 2002). However, when subjects are categorized in tertiles of 
BMD change, there is no correlation between risk reduction of 
vertebral fractures and the tertiles of BMD change (Bjarnason 
et al 2001; Delmas et al 2002), strongly suggesting the 
importance and the role, beside the increase in bone density, 
of others issues not considered before in the fracture 
prevention risk.
Thus, this section will review the differential mechanism(s) 
of action of the most used antiresorptive molecules and their 
clinical use.Clinical Interventions in Aging 2007:2(1) 57
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Mechanism of action 
of bisphosphonates
Bisphosphonates (BPs) are potent selective inhibitors 
of osteoclastic bone resorption and are commonly used 
clinically for the treatment and prevention of postmenopausal 
osteoporosis. These compounds are analogues of naturally 
occurring pyrophosphate (P-C-P) which bind to hydroxyapatite 
crystals. BPs are traditionally divided into non-nitrogen-
containing and nitrogen-containing molecules. Clodronate, 
etidronate, and pamidronate belong to the ﬁ  rst group while 
alendronate, risedronate, ibandronate, and zoledronate belong 
to the second group. The addition of nitrogen group in the 
molecules modiﬁ  es their potency with a ratio ranging from 
100:1 to 10000:1 (Figure 1). Nitrogen-containing BPs (N-BPs) 
reduce osteoclast function by inhibiting farnesyl diphosphate 
synthase, an enzyme which is active in the mevalonate path-
way of the cholesterol biosynthesis. Depletion of farnesyl 
diphosphate or geranylgeranyl diphosphate levels limits 
the prenylation of small GTP-containing proteins (eg, Rho, 
Rac, cdc42, and Rab), essential for osteoclast functions and 
survival, leading to cell apoptosis (Reszka and Rodan 2004). 
At cellular level N-BPs blunt differentiation and recruitment 
of osteoclast precursors from the common hematopoietic 
stem cell, strongly decreasing the number of mature active 
osteoclasts. Additionally, N-BPs inhibit osteoclast adhe-
sion to the mineralized matrix, reduce the osteoclast life 
span by activation of pro-apoptotic caspases, and directly 
inhibit osteoclast activity by alteration in the cytoskeleton, 
including cell morphology, integrin signaling, and disruption 
of the rufﬂ  ed border and trafﬁ  cking of the endosomes 
(Benford et al 2001).
In contrast, non-N-BPs have little effect on the 
mevalonate pathway, but instead they are incorporated into 
intracellular adenosine triphosphate (ATP) analogues that 
have no releasable energy content, thus leading to cell death 
(Figure 2). Subsequent to this str ong inhibition of osteoclast 
activity, bone resorption is almost completely blocked at the 
level of basic multicellular units, BMU (Seeman 2003a), with 
a consequent blockade of bone remodeling.
Thus, BPs combat the three mechanisms causing bone 
loss by: a) reducing the rate of bone remodeling; b) reduc-
ing the negative balance in the bone modeling BMU by 
decreasing number and depth of resorption cavities; and c) 
increasing the mineral content (density) of the bone (Seeman 
2003a). However, studies carried on in experimental animal 
models would indicate that BPs in part differ in their mode 
of action suggesting, for instance, that risedronate reduces 
resorption depth and increases mean wall thickness while 
alendronate reduces cortical porosity (Boyce et al 1995; 
Roschger et al 2001).
Bisphosphonates are retained over time in the skeleton 
and may exert long-term effects and their biological half-
lives may vary and depend on the rate of bone turnover, 
potency, and binding afﬁ  nity of each one to bone. An extended 
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Figure 2 Schematic representation of the mevalonate pathway and the effects of 
the nitrogen-containing bisphosphonate.
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half-life may be beneﬁ  cial, because it may prolong a residual 
effect of the agent after treatment discontinuation. On the 
other hand, prolonged marked suppression of bone turnover 
may have a theoretical negative effect on the ability of bone 
cells to repair microdamages with consequent deterioration 
of bone quality.
Interestingly, the different potency of the BPs allows 
differential dosages and pattern of administration (orally vs 
intravenously, daily vs weekly, or bi/monthly), which allows 
a better personalization of therapeutical intervention.
Clinical use of bisphosphonates
Two different BPs, alendronate and risedronate, are currently 
approved and marketed for osteoporosis prevention and treat-
ment. A third agent, ibandronate, is currently being studied in 
a once-monthly regimen, but it is not as yet in clinical use.
Alendronate treatment has demonstrated a decrease in 
bone turnover and an increase in bone mass up to 8% versus 
placebo at the vertebral level and 6% versus placebo in the 
hip over three years in several clinical trials (Liberman et al 
1995; Cranney et al 2002). More importantly, alendronate 
reduces the occurrence of vertebral fracture and height loss. 
The Fracture Intervention Trial (FIT) has provided evidence 
in over 2000 women with prevalent vertebral fractures (FIT 1) 
that daily alendronate treatment reduces vertebral fractures 
risk by about 50%, multiple vertebral fractures by up to 90%, 
and hip fractures by up to 50% (Liberman et al 1995; Black 
et al 1996). A later study in women with low bone density 
showed reduction in incidence (47%) of all nonvertebral 
fractures (Pols et al 1999). The weekly alendronate treat-
ment (70 mg) has shown the same antifracture efﬁ  cacy of 
the daily regimen.
Risedronate is another potent bisphosphonate that 
produces very positive effects on bone mass and bone 
turnover, with lumbar spine bone mass increases up to 7% 
versus placebo and trochanteric bone mass increases of 
up to 4% versus placebo over 3 years (Harris et al 1999; 
Reginster et al 2000). Furthermore, risedronate has been 
shown to prevent bone loss and to preserve trabecular 
architecture in early postmenopausal (age 52 years) women 
(Dufresne et al 2003). This molecule has been shown to 
reduce the risk of vertebral and nonvertebral fractures early 
in the course of therapy (within 6 months of initiation) in 
postmenopausal women (Harrington et al 2004; Roux et al 
2004) with sustained protection through up to 7 years of 
therapy in several large clinical trials (Harris et al 1999; 
Reginster et al 2000; McClung et al 2001;Sorensen et al 
2003): Vertebral Efﬁ  cacy with Risedronate Therapy–North 
America (VERT1), Vertebral Efﬁ  cacy with Risedronate 
Therapy–Multinational (VERT2), and the Hip Intervention 
Program (HIP).
The VERT studies (over 3000 women with established 
osteoporosis) indicate that 3 years’ risedronate treatment 
reduces the risk of vertebral fractures by 40% to 50%. (Harris 
et al 1999; Reginster et al 2000), while the HIP study (the 
largest osteoporosis treatment trial ever performed) was 
designed to evaluate hip fracture efﬁ  cacy of risedronate 
(McClung et al 2001; Sorensen et al 2003).
Ibandronate is a potent N-BP, which has been extensively 
studied in clinical development for its potential to be 
administered less frequently than at weekly intervals. 
Uniquely, ibandronate can be administered either orally 
or intravenously, with an interval of >2 months. Oral 
ibandronate, when administered either daily or intermittently, 
demonstrates important antifracture efﬁ  cacy at the spine and 
hip (50%–60% risk reduction versus placebo), accompanied 
by signiﬁ  cant increases in BMD at the spine and hip, and 
suppression of bone turnover markers in postmenopausal 
women (Tankó et al 2003; Chesnut et al 2004; McClung 
et al 2004; Reginster 2005). Studies of intermittent 
intravenous ibandronate in postmenopausal osteoporotic 
women have shown a dose-related increase in BMD and bone 
turnover marker suppression comparable with those obtained 
with the proven effective oral ibandronate regimen. In these 
trials, the oral and intravenous ibandronate regimens were 
well tolerated. Ongoing large multinational clinical trials are 
investigating two intermittent ibandronate regimens (once-
monthly oral and intermittent intravenous injections), which 
are expected to provide an optimal combination of efﬁ  cacy, 
tolerability, and patient convenience, leading to improved 
treatment adherence (Tankó et al 2003; Chesnut et al 2004; 
McClung et al 2004; Reginster 2005).
The optimal duration of therapy with BPs is still unknown 
but since they are retained over time in the skeleton and may 
exert long-term effects, a 5–7 year course is probably safe 
and effective on the basis of clinical trial data. Moreover, a 
safe clinical choice might be in aged patients or in patients 
with a high turnover.
Bisphosphonates must be taken with water and on an 
empty stomach to avoid interference with drug absorption 
since it is poorly absorbed. BPs are contraindicated in patients 
who have esophageal stricture or inadequate emptying of 
the esophagus due to the potential for esophageal irritation. 
Although there was no increased risk in clinical trials, Clinical Interventions in Aging 2007:2(1) 59
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patients are recommended to remain upright after taking the 
medication for at least 30 minutes and until after the ﬁ  rst food 
of the day. Safety proﬁ  les appear signiﬁ  cantly improved with 
the once-weekly dosing of alendronate which, as already 
mentioned, is therapeutically equivalent to daily dosing 
(Bauer et al 2000; Schnitzer et al 2000).
Mechanism of action of SERMs
Endogenous 17β−estradiol exerts a protective effect on 
bone; for this reason estrogen replacement therapy (ERT) 
has been reported to be clinically useful in preventing bone 
loss in postmenopausal osteoporosis (Lindsay 1976; Kalu et 
al 1991). Unfortunately, long-term ERT is associated with a 
number of undesirable side effects, including an increased 
risk of uterine and breast cancer and cardiovascular events 
(Barrett-Connor 1992; Compston 1992; Colditz et al 1995; 
Cauley et al 1996; WHI 2002). Therefore, there has been 
the need for a “ideal” compound mimicking the beneﬁ  cial 
effects of estrogen on skeletal tissue, without producing 
the adverse effects of long-ERT on reproductive tissues 
(Sahiner et al 1998). SERMs describe a new class of estrogen 
receptor-binding chemicals (Sato 1992, McDonnell 2000) 
that exert estrogen-agonistic effects in some target tissue 
such as bone and lipid metabolism and estrogen-antagonistic 
effects on uterine endometrium and breast tissue (Ravnikar 
1992; Kauffman and Bryant 1995; Ke et al 1995; Yang 
et al 1996; Delmas et al 1997; Walsh et al 1998; Cummings 
et al 1999).
Clinically available SERMs fall into two chemical 
classes: triphenylethylenes and benzothiofenes (Figure 3). 
Tamoxifen, a triphenylethylene, belongs to the ﬁ  rst genera-
tion of SERM, exhibits antagonist activity in mammary tissue 
(Short et al 1996) and produces estrogen agonist effects on 
bone (Powles et al 1996) and lipids (Decensi et al 1998); 
however tamoxifen produces an estrogen-like stimulation 
of the uterus in ovariectomized rats (Sato and Bryant 1996) 
and only partially antagonizes estrogen-induced uterine 
stimulation (Bryant et al 1995). For this reason, tamoxifen’s 
only clinical application is as chemotherapetical option in 
oncologic patients affected by estrogen receptor-positive 
breast cancer.
The partial agonist effect of tamoxifen on the uterus 
(Tomas et al 1995) is completely abolished in the newly 
developed second generation of SERM, Raloxifene (RAL). 
RAL, a benzothiophene, was developed speciﬁ  cally to avoid 
the uterotrophic effects of other SERMs, and is currently 
approved for prevention and treatment of postmenopausal 
osteoporosis (Riggs and Hartmann 2003). RAL exerts its 
effects by the binding with the estrogen receptor (ER). 
Bone cells express two estrogen receptors, α and β (Vidal 
et al 1999), which belong to the large nuclear steroid/thyroid 
hormone receptor family of ligand-dependent transcription 
factors (Evans 1988. Like other member of the superfamily 
ERs have several functional domains: the N-terminal A/B 
domain containing the ligand-independent transcription 
activation function-1 (AF-1), the C (DNA-binding) 
domain, the D (hinge) domain, and the C-terminal E/F 
(ligand-binding) domain containing the ligand-dependent 
transcription activation function-2 (AF- 2) (Nilsson and 
Gustafsson 2002; Kumar and Thompson 1999) (Figure 4).
Estrogens diffuse into cells and binds to the ERs, triggering 
ER dimerization as well as a speciﬁ  c conformational change 
(Jensen 1991). This change facilitates binding of coregulatory 
proteins that modify and activate its transcriptional activity 
on speciﬁ  c consensus ER response elements in the promoter 
regions of target genes. Analyses of the molecular structure 
of ERα crystals complexed to raloxifene or estradiol 
have conﬁ  rmed that raloxifene and estrogen interact with 
the ligand-binding domain, with minor conformational 
differences (Brzozowski et al 1997).
RAL, acting on bone as estrogen, modulates skeletal 
homeostasis by decreasing bone remodeling to the 
premenopausal range, diminishing activity of osteoclasts, 
but at the same time maintaining the physiological function 
of osteoblasts (Taranta et al 2002). RAL, by a direct ER-
dependent mechanism, decreases osteoclast differentiation 
from hematopoietic precursors, without increasing cell 
apoptosis. At the same time, RAL decreases osteoclast 
activity, as demonstrated by the decrease on bone resorptive 
activity of osteoclast in an in vitro experimental bone 
resorption assay (Taranta et al 2002). Interestingly, while 
BPs directly act on osteoclasts, RAL appears to act by two 
different and independent mechanisms: a direct action on 
the bone resorbing cell, but also an osteoblast-mediated 
mechanism. Indeed, in vitro data demonstrated that RAL 
inhibits release of cytokines, as interleukin-6 and tumor 
necrosis factor-α (TNF-α) from osteoblasts (Taranta et 
al 2002). Additionally, this molecule also interferes with 
OPG/RANKL/RANK cytokine system, essential for 
osteoclast biology, which strongly suggests that this SERM 
can modulate osteoclast activity by a paracrine osteoblast-
dependent mechanism (Hofbauer et al 2004). Interestingly, 
RAL increased the osteoblast-speciﬁ  c transcription factor 
Cbfa1/Runx2 and α2 procollagen type I chain mRNAs, with Clinical Interventions in Aging 2007:2(1) 60
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a pattern that partially coincided with that of 17β-estradiol 
(Taranta et al 2002), strongly suggesting that this molecule 
could partially act on bone metabolism not fully blocking 
bone remodeling, but instead modulating it as estrogens do 
before menopause. More interestingly, our recent studies 
have demonstrated that RAL treatment is able to decrease 
circulating cytokines levels in postmenopausal osteoporotic 
women (Gianni et al 2004), strongly suggesting that this 
molecule could modulate bone turnover by controlling 
cytokines levels after menopause.
RAL can be defined an antiresorptive agent which 
blunts the excessive bone resorption occurring in the high 
bone turnover state induced by estrogen deﬁ  ciency after the 
menopause.
Clinical use of SERMs
In a large treatment study, over 7700 women with osteoporosis 
were randomly assigned to receive two different doses of RAL 
versus placebo in addition to calcium and vitamin D (Ettinger 
et al 1999). RAL reduced the occurrence of vertebral fracture 
by 30% to 50%; however, in this trial and the 1-year exten-
sion, there were no suggestions of reduced risk of any other 
osteoporotic fracture. However, this study was not speciﬁ  cally 
designed, nor did it have the adequate power to evaluate the 
risk of other fractures. To fully address this point, a large, 
randomized, controlled trial called Raloxifene Use for the 
Heart (RUTH) is under way, which will evaluate nonspine 
fractures as one of its many outcomes.
Raloxifene, like tamoxifen and estrogen, has positive 
effects on other organ systems beside the skeleton in 
postmenopausal women (Fisher et al 1998; Ettinger et al 
1999; Delmas et al 2002; Rossouw et al 2002). One positive 
effect appears to be a reduction in estrogen receptor-positive 
invasive breast cancer occurrence of about 65% over 4 years 
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in women taking raloxifene compared with placebo (Cauley 
et al 2001). The persistence of this effect is still under 
investigation in the RUTH study. Additionally, Raloxifene 
reduces serum total and low-density lipoprotein cholesterol, 
lipoprotein (a), and ﬁ  brinogen. In a recent publication in 
which cardiovascular disease outcomes were evaluated in a 
secondary analysis of participants in the Multiple Outcomes of 
Raloxifene Evaluation (MORE) trial, RAL had no signiﬁ  cant 
effect on cardiovascular events in the whole study population. 
However, when analysis was performed on osteoporotic women 
with increased cardiovascular risk at baseline, those assigned 
to the RAL group had a signiﬁ  cant 40% reduction in risk of 
incident cardiovascular events compared with placebo (Barrett-
Connor et al 2002). Also this effect is under further evaluation 
in the RUTH study. Additionally, RAL is not associated with an 
increase in the risk of uterine cancer or any benign uterine disease, 
but may, like tamoxifen, increase the occurrence of hot ﬂ  ashes 
(Cummings et al 1999) and, similarly to tamoxifen and estrogen, 
increase the risk of venous thromboembolic disease (Delmas et al 
2002). Cognitive-function studies from the osteoporosis treatment 
trial and other smaller studies indicate absence of negative effects 
on cognitive function and no differences in memory or mood 
(Nickelsen et al 1999; Yaffe et al 2001). The optimal duration 
of therapy with raloxifene, as with the other therapies, is still 
unclear, although at least 5 year treatment may be suggested 
and it is probably effective on the basis of clinical trial data in 
the prevention and treatment of postmenopausal osteoporosis. 
Raloxifene must be taken daily, independently of the meal, since 
no food interference has been shown.
Mechanism of action of bone 
forming agents (PTH)
Parathyroid hormone (PTH) has been recognized as an 
anabolic agent in bone tissue for over 70 years (Selye 1932) 
but, until recently, its catabolic activity in maintaining 
plasma calcium homeostasis received most attention. This 
hormone is secreted by the parathyroid glands in response 
to a decreased plasmatic calcium levels, acting to restore 
normocalcemia by increasing the efﬂ  ux of calcium from 
bone, by increasing calcium reabsorption by the kidney 
and, indirectly, by increasing the renal synthesis of 1, 25-
dihydroxyvitamin D, which increases intestinal calcium 
absorption. Whether PTH is catabolic or anabolic in the 
skeleton depends on the manner in which the hormone is 
presented to bone; sustained exposure to elevated PTH 
levels, as seen in hyperparathyroidism, results in bone loss 
whereas intermittent exposure, as occurs following PTH 
injection, increases bone mass. Teriparatide (1-34 PTH) is 
the ﬁ  rst biosynthesized bone forming agent available for 
the treatment of osteoporosis. The active (1-34) appears to 
have the same anabolic effects on bone as PTH, 1-31 PTH, 
and 1-84 PTH (Rehman et al 2003). The molecule’s effects 
are mediated by the binding with a speciﬁ  c receptor in both 
osteoblasts and renal tubular cells (Juppner et al 1991; Usdin 
et al 1999). The binding of the molecule to the PTH receptor-1 
activates adenylate cyclase and several phospholipases (A, 
C, D) and increases intracellular cAMP and calcium levels. 
Acting through these mechanisms all these molecules appear 
anabolic in respect to bone.
Clinical use of bone forming agents
Teriparatide is the only anabolic osteoporosis medication. 
Clinical randomized, controlled trials, conducted to evaluate 
the role of recombinant human parathyroid hormone (rhPTH) 
in postmenopausal women affected by severe osteoporosis, 
show that PTH is highly effective at increasing BMD in 
the spine and throughout the skeleton. Results from biopsy 
and bone turnover indicate that it works by stimulating new 
bone formation on trabecular, endocortical, and periosteal 
bone surfaces by preferentially stimulating osteoblastic 
activity over osteoclastic activity (Dempster et al 2001). 
PTH enhances bone strength by restoring bone architecture 
in both cancellous and cortical bone, expanding bone size as 
well as improving BMD. A large, multicenter, clinical trial 
of teriparatide in postmenopausal women showed signiﬁ  cant 
increase in bone mass at the lumbar spine (9.7%), total hip 
(2.6%), total body bone mineral in teriparatide-treated women 
(Neer et al 2001) as well as a signiﬁ  cant 65% reduction in 
vertebral fractures (Neer et al 2001) and a 53% reduction in 
nonvertebral fractures in teriparatide-treated patients (Neer 
et al 2001). In women with osteoporosis who have been 
previously treated with raloxifene or hormone therapy, it 
appears that PTH maintains the same efﬁ  cacy obtained in 
untreated patients (Cosman and Lindsay 2004), while there 
is a suggestion that prior treatment with alendronate may 
blunt some of skeletal response to PTH (Ettinger et al 2004); 
however, BMD increases signiﬁ  cantly; bone turnover is 
dramatically stimulated; and there are no head-to-head trials 
conﬁ  rming that the BMD effect is smaller than expected in 
these patient groups. Moreover, animal studies indicate that 
even if BMD changes are smaller in response to PTH after 
pretreatment with a bisphosphonate, bone strength may be 
equally increased in the clinical setting as in the animals given 
PTH without prior antiresorptive agents (Ma et al 2003). Clinical Interventions in Aging 2007:2(1) 62
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Therefore, in patients who have been previously on other 
antiresorptive medications, PTH can and should be given 
without being afraid of decreased efﬁ  cacy.
Additionally, due to the innovative mechanism of 
action of this molecule, questions have arisen whether the 
coadministration of teriparatide with other antiresorptive 
agents might have additional positive effects in terms of 
both BMD or fracture risk. One study suggests that there 
is no beneﬁ  t to coadministration of PTH (the intact 1-84 
molecule in this study) with alendronate over PTH alone 
(Black et al 2003). Thus, at this time, on the basis of the 
available clinical data, it is reasonable to propose that PTH 
be used alone in a newly diagnosed, previously untreated 
patient, or in osteoporotic patients previously treated with 
alternative therapeutical options. Additionally, all patients, 
after the PTH course, should be given a potent antiresorptive 
agent to maintain the PTH-induced increased bone mass and 
antifracture efﬁ  cacy.
Parathyroid hormone currently must be administered 
by subcutaneous injection, although alternative modes 
of delivery are being investigated. The Food and Drug 
Administration (FDA) has approved the use of teriparatide for 
2 years in postmenopausal women and men at high risk for 
fracture. It is contraindicated in patients with Paget’s disease 
of the bone or patients with bone metastases and preexisting 
hypercalcemia. The most common side effects associated 
with teriparatide include dizziness and leg cramps.
Additionally, clinical trials have been performed, 
and others are ongoing, to evaluate fracture efﬁ  cacies of 
therapeutical regimen with association of two different anti-
osteoporotic drugs. One small trial of PTH with hormone 
therapy versus hormone therapy alone showed that PTH 
could dramatically reduce vertebral deformity occurrence 
(Cosman et al 2001). On the other hand, association between 
raloxifene with alendronate did not show any therapeutical 
advantages in the association group in comparison with the 
placebo group, which would indicate the lack of further 
advantages in the association group.
Conclusions
In conclusion, by considering all the above described 
differential mechanism of action and clinical studies, it might 
be useful to re-evaluate an approach to osteoporosis treatment 
which gives primary importance to a careful characterization 
of the patient, in terms of skeletal risk factors (ie, bone density 
and quality, remodelling), but also extraskeletal risk factors 
(ie, age, nutritional status, exercise) to optimize therapeutical 
approach to prevent fractures. Therefore, the ﬁ  rst-choice drug 
would be the one that better meets the physician’s needs, but 
also the “expectations” of the patient (Del Puente et al 2004; 
Gandolini et al 2004).
Careful monitoring and evaluation of the presence and/or 
the appearance of contraindications or side effects is required, 
which suggests the need for a second choice drug. Moreover, 
it is essential to realize that the patient will change, and may 
develop different clinical indications over time. In addition, 
speciﬁ  c attention has to be paid to adequate nutritional intake, 
exercise, and hip protection in order to prevent fractures 
(Del Puente et al 2004). Since a wide number of treatment 
options are available, and others are in the process of being 
developed, on the base of their different mechanisms of 
action, it will be possible to customize the best therapeutical 
option for each individual patient.
The ﬁ  eld of bone diseases is rapidly advancing both in 
terms of basic research and clinical investigation. Further 
knowledge may enrich and modify our pharmacological 
approach in the near future.
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